Asia Pharmaceuticals & Healthcare Q3 2018
: Opportunities for pharmaceutical companies in the Asia Pacific region will remain diverse. Multinational drugmakerinterest will be skewed towards the larger markets of the region and the smaller, underdeveloped pharmaceutical markets willpresent the weakest commercial incentives owing to their relative market size and level of pharmaceutical development. Highergrowth opportunities in the smaller emerging markets will present themselves within the generic medicines sector, while the highindustry-associated risk profile will deter any significant investment by innovative drugmakers.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook